SF Healthcare Week: Baird Senior Analyst Brian Skorney comments on Monday's conference news and highlights his top picks ahead for 2026
He discusses Biohaven, Xenon, Biogen, and Sarepta.
17 minutes ago
SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy
Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.
14 hours ago
SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy
He discusses the company's degrader programs, TYK2/JAK1, using myostatin for obesity, and a Kv7 epilepsy program that will have key data this year.
15 hours ago
.png){kind=logo}
